文献速递呼吸道感染呼吸危重症与机械通气

托珠单抗治疗住院COVID-19患者的系统评价与荟萃分析

Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
PubMed 文献 · Respirology · 2021-10-03

该系统评价与荟萃分析纳入52项研究(9项随机对照试验和43项观察性研究),共27,004例住院COVID-19患者,评估托珠单抗的疗效。随机对照试验中托珠单抗与死亡率降低11%相关(RR 0.89,95%CI 0.82-0.96),观察性研究中降低31%(RR 0.69,95%CI 0.58-0.83),且随机对照试验中有创机械通气需求减少19%(RR 0.81,95%CI 0.71-0.93)。托珠单抗与住院中重度至危重型COVID-19患者较低的死亡率和其它临床相关结局相关。

要点

  • 随机对照试验中托珠单抗与住院COVID-19患者死亡率降低11%相关。
  • 观察性研究中托珠单抗与死亡率降低31%相关。
  • 随机对照试验中有创机械通气需求减少19%,观察性研究无显著减少。

核心结论

  • 托珠单抗与住院中重度至危重型COVID-19患者较低的死亡率和其它临床相关结局相关。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、CENTRAL和medRxiv,纳入52项研究(9项随机对照试验和43项观察性研究),共27,004例住院COVID-19患者。

主要发现

  • 随机对照试验中托珠单抗与死亡率降低11%相关(RR 0.89,95%CI 0.82-0.96)。
  • 观察性研究中托珠单抗与死亡率降低31%相关(RR 0.69,95%CI 0.58-0.83)。
  • 随机对照试验中有创机械通气需求减少19%(RR 0.81,95%CI 0.71-0.93),观察性研究中无显著减少。
  • 随机对照试验和观察性研究均显示托珠单抗对死亡率或有创机械通气的复合终点有获益。
  • 托珠单抗改善ICU和非ICU患者的死亡率;观察性研究中无论是否使用全身皮质类固醇死亡率均降低,而随机对照试验中并非如此。

临床怎么用

  • 对于住院中重度至危重型COVID-19患者,可考虑使用托珠单抗以降低死亡率和有创机械通气需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tocilizumab has been repurposed against the 'cytokine storm' in the setting of coronavirus disease 2019 (COVID-19). Our aim was to evaluate the efficacy of tocilizumab in the management of hospitalized COVID-19 patients. We searched MEDLINE, CENTRAL and medRxiv for studies of tocilizumab in hospitalized COVID-19 patients. Primary objective was the effectiveness of tocilizumab on mortality. Secondary objectives included the need for invasive mechanical ventilation (IMV), composite endpoints of mortality or IMV and intensive care unit (ICU) admission or IMV, length of hospitalization and differences in mortality in subgroups (ICU and non-ICU patients and patients receiving or not receiving concomitant corticosteroids). We included 52 studies (nine randomized controlled trials [RCTs] and 43 observational) with a total of 27,004 patients. In both RCTs and observational studies, the use of tocilizumab was associated with a reduction in mortality; 11% in RCTs (risk ratio [RR] 0.89, 95% CI 0.82 to 0.96) and 31% in observational studies (RR 0.69, 95% CI 0.58 to 0.83). The need for IMV was reduced by 19% in RCTs (RR 0.81, 95% CI 0.71 to 0.93), while no significant reduction was observed in observational studies. Both RCTs and observational studies showed a benefit from tocilizumab on the composite endpoint of mortality or IMV. Tocilizumab improved mortality both in ICU and non-ICU patients. Reduction in mortality was evident in observational studies regardless of the use of systemic corticosteroids, while that was not the case in the RCTs. Tocilizumab was associated with lower mortality and other clinically relevant outcomes in hospitalized patients with moderate-to-critical COVID-19.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Kyriakopoulos C, Ntritsos G, Gogali A, et al. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. Respirology. 2021. PMID: 34605114. doi:10.1111/resp.14152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。